Back to School: How biopharma can reboot drug development. Access exclusive analysis here

eFT508: Phase I/II started

Effector began an open-label, dose-escalation, dose-expansion, U.S. Phase I/II trial to evaluate oral

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE